Ingevity Corporation NGVT
73.00
1.21
1.69%
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 47.4×
Follow NGVT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 64.44% | (93.46%) | (148.60%) | (37.38%) |
+8 more TTM periods Free account |
|
| 3.16% | (6.90%) | (9.10%) | (3.26%) | ||
ROIC |
9.33% | (2.43%) | (2.47%) | 10.67% | |
Return on Tangible Assets |
6.91% | (16.55%) | (23.18%) | (8.90%) | |
Average Days of Receivables |
49.01 | 46.86 | 39.76 | 58.54 | |
Free Cash Flow per Share |
4.47 | 6.97 | 7.65 | 6.60 | |
Free Cash Flow |
154.90 | 245.80 | 277.10 | 239.60 | |
Capital Expenditures |
(56.10) | (58.00) | (54.10) | (59.00) | |
Piotroski F-Score |
6.00 | 4.00 | 5.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
16.40% | 23.34% | 26.10% | 21.64% | |
Accounts Receivable Turnover |
6.65 | 7.48 | 9.02 | 5.86 | |
Accounts Payable Turnover |
7.21 | 7.36 | 7.57 | 5.72 | |
Inventory Turnover |
3.65 | 3.17 | 3.70 | 2.48 | |
Average Days of Payables |
47.02 | 43.59 | 47.56 | 65.28 | |
Days of Inventory on Hand |
82.29 | 104.42 | 96.15 | 125.31 | |
Tax Rate |
(0.33) | 0.04 | 0.06 | (0.43) | |
Research and Development Expense of Revenue |
2.34% | 2.39% | 2.43% | 2.40% | |
Selling, General and Administrative Expense of Revenue |
14.25% | 14.43% | 14.66% | 15.35% | |
Share Based Compensation of Revenue |
1.62% | 1.61% | 1.57% | 1.52% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
3.91 | (2.38) | (1.98) | (4.53) | |
Depreciation/Fixed assets |
0.18 | 0.48 | 0.48 | 0.46 | |
Capex/Depreciation |
(0.56) | (0.20) | (0.19) | (0.21) | |
Revenue per Share |
33.45 | 33.40 | 32.23 | 28.87 | |
Operating CF per Share |
6.08 | 8.62 | 9.14 | 8.22 | |
Capex per Share |
(1.62) | (1.65) | (1.49) | (1.62) | |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.06 | |
Net Profit Margin |
4.65% | (10.85%) | (14.31%) | (6.29%) |
Columns are period end dates